Genetic and environmental risk assessment and colorectal cancer screening in an average-risk population: A randomized trial

Annals of Internal Medicine

Volumn 161, Issue 8, 2014, Pages 537-545

  Weinberg, David S ^a   Myers, Ronald E ^b   Keenan, Eileen ^a   Ruth, Karen ^a   Sifri, Randa ^b   Ziring, Barry ^b   Ross, Eric ^a   Manne, Sharon L ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Park Avenue Neurology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FEMALE; FOLIC ACID BLOOD LEVEL; GENETIC AND ENVIRONMENTAL RISK ASSESSMENT; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SCHOOL; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; BLOOD; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; MIDDLE AGED; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; RISK; UTILIZATION;

AGED; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PATIENT COMPLIANCE; POLYMORPHISM, GENETIC; RISK; RISK ASSESSMENT;

EID: 84924930049     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-0765     Document Type: Article

References (35)

1. Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, et al; American Cancer Society Colorectal Cancer Advisory Group. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134: 1570-95. [PMID: 18384785] doi: 10.1053/j.gastro.2008.02.002
2. Ghazarian AA, Simonds NI, Bennett K, Pimentel CB, Ellison GL, Gillanders EM, et al. A review of NCI's extramural grant portfolio: Identifying opportunities for future research in genes and environment in cancer. Cancer Epidemiol Biomarkers Prev. 2013;22: 501-7. [PMID: 23462918] doi: 10.1158/1055-9965.EPI-13-0156
3. Green ED, Guyer MS; National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470: 204-13. [PMID: 21307933] doi: 10.1038/nature09764
4. McBride CM, Bryan AD, Bray MS, Swan GE, Green ED. Health behavior change: Can genomics improve behavioral adherence? Am J Public Health. 2012; 102: 401-5. [PMID: 22390502] doi: 10.2105/AJPH.2011.300513
5. Kim YI. Folate and cancer prevention: A new medical application of folate beyond hyperhomocysteinemia and neural tube defects. Nutr Rev. 1999;57: 314-21. [PMID: 10575908]
6. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res. 1997;57: 1098-102. [PMID: 9067278]
7. Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med. 2001;138: 164-76. [PMID: 11528369]
8. Keku T, Millikan R, Worley K, Winkel S, Eaton A, Biscocho L, et al. 5, 10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev. 2002;11: 1611-21. [PMID: 12496052]
9. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med. 1998;129: 517-24. [PMID: 9758570]
10. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: A systematic review. JAMA. 2008;299: 1320-34. [PMID: 18349093] doi: 10.1001/jama.299.11.1320
11. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008;10: 19-32. [PMID: 18197053] doi: 10.1097/GIM.0b013e31815f524f
12. McBride CM, Koehly LM, Sanderson SC, Kaphingst KA. The behavioral response to personalized genetic information: Will genetic risk profiles motivate individuals and families to choose more healthful behaviors? Annu Rev Public Health. 2010;31: 89-103. [PMID: 20070198] doi: 10.1146/annurev.publhealth.012809.103532
13. Ransohoff DF, Khoury MJ. Personal genomics: Information can be harmful. Eur J Clin Invest. 2010;40: 64-8. [PMID: 20055897] doi: 10.1111/j.1365-2362.2009.02232.x
14. Bloss CS, Wineinger NE, Darst BF, Schork NJ, Topol EJ. Impact of direct-To-consumer genomic testing at long term follow-up. J Med Genet. 2013; 50: 393-400. [PMID: 23559530] doi: 10.1136/jmedgenet-2012-101207
15. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-Associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105: 175-201. [PMID: 23297039] doi: 10.1093/jnci/djs491
16. Qaseem A, Denberg TD, Hopkins RH Jr, Humphrey LL, Levine J, Sweet DE, et al; Clinical Guidelines Committee of the American College of Physicians. Screening for colorectal cancer: A guidance statement from the American College of Physicians. Ann Intern Med. 2012;156: 378-86. [PMID: 22393133] doi: 10.7326/0003-4819-156-5-201203060-00010
17. Myers RE, Manne SL, Wilfond B, Sifri R, Ziring B, Wolf TA, et al. A randomized trial of genetic and environmental risk assessment (GERA) for colorectal cancer risk in primary care: Trial design and baseline findings. Contemp Clin Trials. 2011;32: 25-31. [PMID: 20828635] doi: 10.1016/j.cct.2010.08.013
18. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: A measure of subjective stress. Psychosom Med. 1979;41: 209-18. [PMID: 472086]
19. Wilfond BS, Fost N. The cystic fibrosis gene: Medical and social implications for heterozygote detection. JAMA. 1990;263: 2777-83. [PMID: 11653890]
20. Konings EJ, Goldbohm RA, Brants HA, Saris WH, van den Brandt PA. Intake of dietary folate vitamers and risk of colorectal carcinoma: Results from The Netherlands Cohort Study. Cancer. 2002;95: 1421-33. [PMID: 12237910]
21. Houlston RS, Tomlinson IP. Polymorphisms and colorectal tumor risk. Gastroenterology. 2001;121: 282-301. [PMID: 11487538]
22. Pufulete M, Al-Ghnaniem R, Leather AJ, Appleby P, Gout S, Terry C, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: A case control study. Gastroenterology. 2003;124: 1240-8. [PMID: 12730865]
23. Ulvik A, Evensen ET, Lien EA, Hoff G, Vollset SE, Majak BM, et al. Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am J Med Genet. 2001;101: 246-54. [PMID: 11424140]
24. McDowell MA, Lacher DA, Pfeiffer CM, Mulinare J, Picciano MF, Rader JI, et al. Blood folate levels: The latest NHANES results. NCHS Data Brief. 2008: 1-8. [PMID: 19389320]
25. Cella D, Hughes C, Peterman A, Chang CH, Peshkin BN, Schwartz MD, et al. A brief assessment of concerns associated with genetic testing for cancer: The Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 2002;21: 564-72. [PMID: 12433008]
26. Botto LD, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol. 2000;151: 862-77. [PMID: 10791559]
27. Smith RA, Duffy SW, Tabár L. Breast cancer screening: The evolving evidence. Oncology (Williston Park). 2012;26: 471-5, 479-81, 485-6. [PMID: 22730603]
28. Evans JP, Meslin EM, Marteau TM, Caulfield T. Genomics. Deflating the genomic bubble. Science. 2011;331: 861-2. [PMID: 21330519] doi: 10.1126/science.1198039
29. Marteau TM, French DP, Griffin SJ, Prevost AT, Sutton S, Watkinson C, et al. Effects of communicating DNA-based disease risk estimates on riskreducing behaviours. Cochrane Database Syst Rev. 2010: CD007275. [PMID: 20927756] doi: 10.1002/14651858.CD007275.pub2
30. Reid RJ, McBride CM, Alford SH, Price C, Baxevanis AD, Brody LC, et al. Association between health-service use and multiplex genetic testing. Genet Med. 2012;14: 852-9. [PMID: 22595941] doi: 10.1038/gim.2012.52
31. Bloss CS, Schork NJ, Topol EJ. Effect of direct-To-consumer genomewide profiling to assess disease risk. N Engl J Med. 2011;364: 524-34. [PMID: 21226570] doi: 10.1056/NEJMoa1011893
32. Giles J. Social science lines up its biggest challenges. Nature. 2011;470: 18-9. [PMID: 21293348] doi: 10.1038/470018a
33. O'Neill SC, McBride CM, Alford SH, Kaphingst KA. Preferences for genetic and behavioral health information: The impact of risk factors and disease attributions. Ann Behav Med. 2010;40: 127-37. [PMID: 20532842] doi: 10.1007/s12160-010-9197-1
34. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
35. Parsons LS. Performing a 1:N Case-Control Match on Propensity Score. Presented at the Twenty-Ninth Annual SAS Users Group International Conference (SUGI 29), Montréal, Québec, Canada, 9-12 May 2004. Paper 165-29.